Buspirone induced prolactin release in mania.
Prolactin responses to buspirone challenge were examined in 11 manic patients and 11 healthy controls. Of the 11 manic patients, six were treated with lithium alone for 3 weeks, and the buspirone challenge test was repeated. The results showed (1) that there was no difference in prolactin response to buspirone challenge between manic patients and healthy controls, and (2) that there was no correlation between delta (delta) prolactin levels and severity of manic symptoms. Lithium treatment led to a large reduction in delta (delta) prolactin levels, which did not correlate with changes in symptom severity. These results support the possibility that 5HT1A receptors are probably not involved in the pathophysiology of mania.